Prediction of 2 years-survival in patients with stage I and II non-small cell lung cancer utilizing (18)F-FDG PET/CT SUV quantification.
Prediction of 2 years-survival in patients with stage I and II non-small cell lung cancer utilizing (18)F-FDG PET/CT SUV quantification.
复制标题
DOI：
10.2478/raon-2013-0023
复制
发表时间：
2013
影响因子：
2.4
通讯作者：
Baldari S
中科院分区：
文献类型：
--
作者：
Cistaro A;Quartuccio N;Mojtahedi A;Fania P;Filosso PL;Campenni A;Ficola U;Baldari S
本研究的目的是评价I、II期非小细胞肺癌（NSCLC）患者2年随访时最大标准化摄取值（SUVmax）、原发病灶大小、无病生存期（DFS）和总生存期（OS）之间的相关性。本研究纳入了49例I-II期NSCLC患者。对所有患者进行术前2-脱氧-2-[18 F]氟-D-葡萄糖正电子发射断层扫描（18 F-FDG PET/CT）研究。测量SUVmax、肿瘤大小和临床结果之间的关系。计算具有最佳预后意义的SUVmax和肿瘤大小的截止值、DFS的概率以及SUVmax与治疗反应之间的相关性。SUVmax和DFS之间存在统计学显著相关性（p = 0.029）。SUVmax的最佳临界值为9.00（p = 0.0013），肿瘤大小的最佳临界值为30 mm（p = 0.0028）。SUVmax > 9且原发病灶大小> 30 mm的患者的预期2年无病生存率为37.5%，而如果肿瘤<30 mm和/或SUVmax <9，则该预期2年无病生存率上升至90%。在I-II期，SUVmax和肿瘤大小可能有助于确定复发机会高的患者亚组。
The purpose of the study was to evaluate the correlation between the maximum standardized uptake value (SUVmax), size of primary lung lesion, disease-free survival (DFS) and overall survival (OS) in patients with stage I and II non-small cell lung cancer (NSCLC) in 2 years follow-up. Forty-nine patients with stage I–II NSCLC were included in this study. Pre-surgical 2-deoxy-2-[18F]fluoro-D-glucose positron-emission tomography (18F-FDG PET/CT) study was performed for all patients. The relationship between SUVmax, tumour size and clinical outcome was measured. The cut-off value for SUVmax and tumour size with the best prognostic significance, probability of DFS and the correlation between SUVmax and the response to therapy were calculated. There was a statistically significant correlation between SUVmax and DFS (p = 0.029). The optimal cut-offs were 9.00 for SUVmax (p = 0.0013) and 30mm for tumour size (p = 0.0028). Patients with SUVmax > 9 and primary lesion size > 30 mm had an expected 2years-DFS of 37.5%, while this rose to 90% if the tumour was <30 mm and/or SUVmax was <9. In stage I-II, SUVmax and tumour size might be helpful to identify the subgroup of patients with high chance for recurrence.
登录
查看更多内容
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
DOI：
10.2967/jnumed.111.095257
发表时间：
2011-11
期刊：
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
影响因子：
--
作者：
Benz MR;Herrmann K;Walter F;Garon EB;Reckamp KL;Figlin R;Phelps ME;Weber WA;Czernin J;Allen-Auerbach MS
通讯作者：
Allen-Auerbach MS
影响因子：
8.4
作者：
van Baardwijk, Angela;Dooms, Christophe;De Ruysscher, Dirk
通讯作者：
De Ruysscher, Dirk
影响因子：
20.4
作者：
Goodgame, Boone;Pillot, Giancarlo A.;Govindan, Ramaswamy
通讯作者：
Govindan, Ramaswamy
影响因子：
1.5
作者：
Jeong, HJ;Min, JJ;Shim, YS
通讯作者：
Shim, YS